CALT calliditas.se: Multiplikator Forward P/S

Calliditas Therapeutics (CALT) faces risks due to its dependence on the drug Tarpeyo and ongoing patent disputes. The Swedish developer's revenues are based on the treatment of IgA nephropathy via payments from US and European insurance systems. The environmental footprint remains minimal due to production outsourcing. The expected P/S metric demonstrates a shift in market phases, and 7.10 determines the latest valuation figure.

Calliditas Therapeutics, Inc. - Multiplikator Forward P/S CALT (periode 08.01.2023 - 28.09.2024)

calliditas.se (CALT) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:

Kutipan saham Calliditas Therapeutics AB|CALT - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar Calliditas Therapeutics AB|CALT - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- statistik nilai buku emiten:

Nilai Buku saben Saham Calliditas Therapeutics|CALT - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku calliditas.se|CALT - Aset Agregat Perusahaan

- data tingkat utang lan likuiditas finansial:

Utang marang Ekuitas Calliditas Therapeutics|CALT - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Calliditas Therapeutics AB|CALT - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Calliditas Therapeutics AB|CALT - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Calliditas Therapeutics|Indikator likuiditas cepet calliditas.se

- rincian asil keuangan lan kelipatan valuasi:

CALT - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Calliditas Therapeutics|CALT - Pangali P/E|Rega marang bathi mangsa ngarep Calliditas Therapeutics AB|CALT - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Calliditas Therapeutics AB|CALT - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Calliditas Therapeutics|CALT - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan calliditas.se|CALT - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Calliditas Therapeutics

- data total pendapatan lan volume dodolan:

CALT - Total pendapatan perusahaan|Prakiraan pendapatan perusahaan Calliditas Therapeutics AB|CALT - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S Calliditas Therapeutics AB

Analisis komprehensif perusahaan:Calliditas CALT

The forward P/S reflects the ratio of the current market value of Calliditas Therapeutics (CALT) to expected sales, allowing for a determination of whether a low price results from a systemic business decline. By analyzing the forward P/S valuation, an investor identifies the fair value of the asset, which for Calliditas Therapeutics (CALT) is further supported by high business resilience due to the neutral status of the biomedical sector and the absence of geopolitical risks.

Analisis pesaing Calliditas Therapeutics

Travere Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Ardelyx Inc (ARDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ProKidney Inc. - Multiplikator Forward P/S|Akebia Corp (AKBA) - Multiplikator forward rega marang pendapatan|TVRD: Multiplikator Forward P/S|diamedica.com (DMAC) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Unicycive Therapeutics, Inc.|Rasio rega marang prakiraan pendapatan RMTI|Rasio rega marang prakiraan pendapatan Cadrenal Therapeutics, Inc (CVKD)|Rasio rega marang prakiraan pendapatan CDT (Conduit Therapeutics)|Multiplikator Forward P/S RNLX (Renalytix Plc)|Rasio kapitalisasi marang dodolan sing dikarepake ZyVersa Therapeutics Inc. (ZVSA)